The binding of polypeptide growth factors to their appropriate cell surface transmembrane receptors triggers numerous biochemical responses, including the transcriptional activation of specific genes. We have used a differential display approach to identify fibroblast growth factor-1-inducible genes in murine NIH 3T3 cells. Here, we report that the fibroblast growth factorinducible-14 (Fn14) gene is a growth factor-regulated, immediate-early response gene expressed in a developmental stage-and adult tissue-specific manner in vivo. This gene, located on mouse chromosome 17, is predicted to encode an 129-amino acid type Ia membrane protein with no significant sequence similarity to any known protein. We have used two experimental approaches, direct fluorescence microscopy and immunoprecipitation analysis of biotinylated cell surface proteins, to demonstrate that Fn14 is located on the plasma membrane. To examine the biological consequences of constitutive Fn14 expression, we isolated NIH 3T3 cell lines expressing variable levels of epitope-tagged Fn14 and analyzed their phenotypic properties in vitro. These experiments revealed that Fn14 expression decreased cellular adhesion to the extracellular matrix proteins fibronectin and vitronectin and also reduced serum-stimulated cell growth and migration. These results indicate that Fn14 is a novel plasma membrane-spanning molecule that may play a role in cell-matrix interactions.Complex cellular processes such as proliferation, migration, differentiation, and apoptosis are regulated in part by a diverse group of molecules known as polypeptide growth factors. These factors act by binding and thereby activating specific transmembrane receptor tyrosine kinases. The activation of cell surface receptors by polypeptide ligands triggers downstream intracellular events, including the stimulation of protein phosphorylation cascades and the transcriptional activation of numerous genes (1, 2). Many mitogen-inducible genes have been identified, and they encode a diverse group of proteins including transcription factors, protein kinases and phosphatases, cell cycle regulators, and cytoskeletal and extracellular matrix proteins (2, 3). A recent study using cDNA microarray technology has demonstrated that Ͼ500 genes are transcriptionally activated after serum stimulation of quiescent human fibroblasts and that a subset of these genes encode proteins implicated in the wound healing process in vivo (3).Our laboratory has been studying fibroblast growth factor-1 (FGF-1) 1 -regulated gene expression in murine NIH 3T3 cells. FGF-1 (also referred to as acidic FGF) is one of the most extensively characterized members of the FGF family of heparin-binding proteins (4 -6). It is a potent mitogenic, chemotactic, angiogenic, and neurotrophic factor both in vitro and in vivo. These cellular responses are mediated via high affinity binding to a family of related membrane-spanning tyrosine kinase receptors (4 -6). We have shown by Northern blot hybridization analysis that FGF-1 stimulation of quies...

Fibroblast growth factor (FGF)-1 mitogenic signal transduction is mediated in part by gene products that are specifically expressed in response to cell surface receptor binding and activation. We have used a targeted differential display method to identify FGF-1-inducible genes in murine NIH 3T3 fibroblasts. Here we report that one of these genes is predicted to encode a novel serine/threonine-specific protein kinase. This putative kinase has been named Fnk, for FGF-inducible kinase. The deduced Fnk amino acid sequence has 49, 36, 33, 32, and 22% overall identity to mouse serum-inducible kinase (Snk), mouse polo-like kinase (Plk), Drosophila polo, Saccharomyces Cdc5, and mouse Snk/Plk-akin kinase (Sak), respectively. These proteins are all members of the polo subfamily of structurally related serine/threonine kinases. The Plk, polo, Cdc5, and Sak kinases are required for cell division. FGF-1 induction of Fnk mRNA expression is first detected at 30 min after mitogen addition, reflects transcriptional activation, and does not require de novo protein synthesis. FGF-2, platelet-derived growth factor-BB, calf serum, or phorbol myristate acetate treatment of quiescent cells also induces fnk gene expression. Fnk mRNA is expressed in vivo in a tissue-specific manner, with relatively high levels detected in newborn and adult mouse skin. These results indicate that Fnk may be a transiently expressed protein kinase involved in the early signaling events required for growth factor-stimulated cell cycle progression.

Polypeptide growth factors stimulate mammalian cell proliferation by binding to specific cell surface receptors. This interaction triggers numerous biochemical responses including the activation of protein phosphorylation cascades and the enhanced expression of specific genes. We have identified several fibroblast growth factor (FGF)-inducible genes in murine NIH 3T3 cells and recently reported that one of them, the FGF-inducible 14 (Fn14) immediate-early response gene, is predicted to encode a novel, cell surfacelocalized type Ia transmembrane protein. Here, we report that the human Fn14 homolog is located on chromosome 16p13.3 and encodes a 129-amino acid protein with ϳ82% sequence identity to the murine protein. The human Fn14 gene, like the murine Fn14 gene, is expressed at elevated levels after FGF, calf serum or phorbol ester treatment of fibroblasts in vitro and is expressed at relatively high levels in heart and kidney in vivo. We also report that the human Fn14 gene is expressed at relatively low levels in normal liver tissue but at high levels in liver cancer cell lines and in hepatocellular carcinoma specimens. Furthermore, the murine Fn14 gene is rapidly induced during liver regeneration in vivo and is expressed at high levels in the hepatocellular carcinoma nodules that develop in the c-myc/transforming growth factor-␣-driven and the hepatitis B virus X protein-driven transgenic mouse models of hepatocarcinogenesis. These results indicate that Polypeptide mitogens such as fibroblast growth factor (FGF)-1 and platelet-derived growth factor-BB stimulate cell cycle progression by binding to specific receptor tyrosine kinases and thereby activating intracellular signal transduction pathways.1 The activation of cytoplasmic signaling molecules promotes changes in gene expression that are critical for the cellular growth response. Numerous growth factor-and/or serum-inducible genes have been identified and classified into one of three groups: immediate-early, delayed-early, or late response genes.2 Immediate-early response genes are rapidly and transiently expressed following mitogenic stimulation of quiescent cells and their transcriptional activation does not require de novo protein synthesis. Delayed-early response genes are first expressed a few hours later, in the early to middle portions of the G1 phase, and transcript levels often remain elevated for the remainder of the cell cycle. Late response genes are generally expressed only during the S phase of the cell cycle. Both delayed-early and late response genes require de novo protein synthesis for their transcriptional activation. Growth factor-inducible genes encode many types of proteins, including transcription factors, cell cycle regulators, extracellular matrix proteins and metabolic enzymes. [2][3][4]

No abstract

In a two-dimensional (2D) culture dish, the major activity of endothelial cells is proliferation with limited morphological change. When cultured in a three-dimensional (3D) collagen gel matrix, endothelial cells undergo a series of morphological changes starting with development of intracellular vacuoles and followed by cell elongation. Adjacent cells then coalesce to form tube-like structures. This process mimics the steps of capillary formation during angiogenesis. Using this model, we investigated the roles of extracellular signal-regulated kinase (ERK) and p38 MAP kinase (p38) in the tube formation from human umbilical vein endothelial cells (HUVEC). Proliferating HUVEC gradually lost their ability to divide after being transferred to 3D collagen matrices, where differentiation became the dominant cellular activity. The transition from proliferation to the differentiation state was accompanied by a drastic reduction of cyclin-dependent kinases CDC2, CDK4, and retinoblastoma (Rb) protein, but the expression of cyclin-dependent kinase inhibitor, p27kip1, was increased. Inhibition of p38 by SB203580 partially prevented these changes and increased the proliferation rate of HUVEC. However, cells under this condition exhibited unusually elongated cell bodies, and they were unable to coalesce to form tube structures. Inhibition of ERK neither affected the cell proliferation rate nor the expression levels of cell cycle regulators, but it completely blocked tube formation by inducing apoptosis, a finding different from the best-known role of ERK in cell proliferation in the 2D cell culture systems. We conclude that the major function of ERK is to maintain cell viability while p38 plays multiple roles in controlling cell proliferation, viability, and morphogenesis during tube formation.

Abstract-Cleaved high molecular weight kininogen (HKa) has been shown to inhibit in vivo neovascularization and induce apoptosis of endothelial cells. We have shown that HKa-induced apoptosis correlated with its antiadhesive effect and was regulated by extracellular matrix (ECM) proteins. In this study, we identified the urokinase-type plasminogen activator receptor (uPAR) as a target of HKa activity at the endothelial cell surface. Anti-uPAR antibodies blocked the apoptotic effect of HKa. Further studies revealed that uPAR formed a signaling complex containing integrin ␣ v ␤ 3 or ␣ 5 ␤ 1 , caveolin, and Src kinase Yes in endothelial cells. HKa physically disrupted the formation of this complex in a manner that paralleled its apoptotic effect. For the first time, our results provide a mechanistic explanation for the previous observation that HKa selectively induces apoptosis of endothelial cells grown on vitronectin, but not cells grown on fibronectin. These data also resolve the controversial role of uPAR in mediating the apoptotic and antiadhesive activities of HKa. Key Words: urokinase-type plasminogen activator receptor Ⅲ high molecular weight kininogen Ⅲ endothelial cells Ⅲ apoptosis Ⅲ angiogenesis A ngiogenesis, the formation of new capillaries from existing blood vessels, is a cellular event crucial for both physiological and pathological processes such as embryogenesis and cancer development, 1 respectively. A positive balance in favor of angiogenic factors leads to new blood vessel formation, whereas the predominance of angiogenic inhibitors will switch the equilibrium to vessel quiescence or vessel regression. [2][3][4][5] High molecular weight kininogen (HK) is a plasma protein that was first identified as a precursor of the bioactive peptide bradykinin. We now recognize that HK is a multifunctional protein that plays important roles in many pathophysiological processes, such as fibrinolysis, thrombosis, and inflammation. 6 HK is a 120-kDa single-chain glycoprotein consisting of six domains (designated as D1 to D6, respectively) with each having distinct functions. 7 After proteolytic cleavage of HK by kallikrein and release of bradykinin contained within D4, the remaining portion of the molecule, HKa, undergoes major conformational changes that lead to a greater surface exposure of the D5 region. As a result, HKa acquires new properties. In comparison with HK, HKa shows an increased antiadhesive effect due to domain rearrangements. 8,9 HK specifically and reversibly binds to endothelial cells in a Zn 2ϩ -dependent manner. Thus, the endothelial cell surface is an important site for the generation of both bradykinin and HKa, each of which regulates the functions of endothelial cells. Although the involvement of bradykinin in the regulation of many physiological and pathophysiological processes has been intensively studied, the functional implications of the generation of HKa are incompletely understood. Recent studies from our laboratory and other investigators indicate that HKa may act as a naturally ...

No abstract

Summary Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factorVIIa (FVIIa).TF is constitutively expressed ina variety of tumor cells and has been shown to playa role in cellular signaling and tumor progression. In this study, we investigated the effect of TF-FVIIa mediated signaling on apoptosis in human breast cancer cells. Apoptosis was induced by prolonged serum starvation and studied using the Adr-MCF-7 cell line, which has high endogenous TF expression. Treatment of the cells with the combination of FVIIa (10 nM) and FX (150 nM), reduced apoptosis by nearly 50% compared with untreated, control cells using an ELISA that detects histone-DNA fragments. In contrast, FVIIa (10 nM) alone did not significantly prevent apoptosis. Pretreatment of the Adr-MCF-7 cells with hirudin, a specific thrombin inhibitor, did not inhibit the anti-apoptotic effect of the combination of FVIIa and FX, whereas this effect could be abrogated by inhibition of phosphorylation of either p44/42 mitogen-activated protein kinase (MAPK) or protein kinaseB (PKB/Akt). In addition, treatment of theAdr-MCF-7 cells with the combination of FVIIa and FX led to a 30-50% increase in the level of the anti-apoptotic protein, survivin, compared with untreated cells usingWestern blot analysis. These results indicate that formation of TF-FVIIa-FXa complex prevents apoptosis in breast cancer cells by a thrombin-independent pathway. Moreover, the anti-apoptotic effect of this signaling pathway involves phosphorylation of both p44/42 MAPK and PKB/Akt and might be mediated in part by an increase in cell survivin levels.